# Rec'd PCT/PTO \_3 DEC 2004 PATENT COOPERATION TREATY REC'D 2 9 JUN 2004

**PCT** 

WIPO	

PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

	Applicant's or agent's file reference 4-32528A/USN			FOR FURTHER	ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)			
PC	International application No. PCT/EP 03/06195			International filing dat 12.06.2003		h/year)	Priority date (day/month/year) 13.06.2002	
A6	International Patent Classification (IPC) or both national classification and IPC A61K31/405							
	Applicant NOVARTIS AG et al.							
1.	<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> </ol>							
2.	2. This REPORT consists of a total of 5 sheets, including this cover sheet.							
	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
	These annexes consist of a total of sheets.					•		
3.	3. This report contains indications relating to the following items:							
	1	$\boxtimes$	Basis of the opinion					
	11		Priority			•		
	111		Non-establishment of op	pinion with regard to I	novelty, inv	entive step ar	nd industrial applicability	
	IV V		Lack of unity of invention					
	V	Ы	citations and explanation	der Rule 66.2(a)(ii) was such st	er Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; supporting such statement			
	VI		Certain documents cited					
	VII		Certain defects in the int	ernational application	า			
	VIII		Certain observations on	the international app	lication			
Date	Date of submission of the demand			Date of completion of this report				
	03.12.2003				28.06.2004			
Name prelim	Name and malling address of the international preliminary examining authority:				Authorized Officer			
	European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465			Fanni, S	6 9 No. +49 89 23	99-8712		

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/06195

4

l. Bas	sis of	the	re	po	rt
--------	--------	-----	----	----	----

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Description, Pages						
	1-15		as originally filed				
	Ci	aims, Numbers					
	1-	14	as originally filed				
2	. W lar	With regard to the <b>language</b> , all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.					
		hese elements were available or furnished to this Authority in the following language: , which is:					
		the language of put	the language of publication of the international application (under Rule 48.3(b)).				
		the language of a tr Rule 55.2 and/or 55	anslation furnished for the nurnoses of international proliminary and in the contraction of the contraction				
3.	Wi	With regard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:					
	☐ contained in the international application in written form.						
			ne international application in computer readable form.				
	furnished subsequently to this Authority in written form.						
	☐ furnished subsequently to this Authority in computer readable form.						
	☐ The statement that the subsequently furnished written sequence listing does not go beyond the distinct in the international application as filed has been furnished.						
	The statement that the information recorded in computer readable form is identical to the written sequentisting has been furnished.						
4.	The amendments have resulted in the cancellation of:						
		the description,	pages:				
		the claims,	Nos.:				
		the drawings,	sheets:				
5.  This report has been established as if (some of) the amendments had not been made, since been considered to go beyond the disclosure as filed (Rule 70.2(c)).							
		(Any replacement sh report.)	eet containing such amendments must be referred to under item 1 and annexed to this				
6.	Additional observations, if necessary:						

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/06195

H	I. No	n-establishment of opinion	with re	egard to nov	elty, inventive step and industrial applicability	
1	<ol> <li>The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:</li> </ol>					
	☐ the entire international application,					
	⊠ claims Nos. 14					
	because:					
	⊠	the said international applica does not require an internation	tion, o	r the said cla eliminary exa	ims Nos. 14 relate to the following subject matter which amination (specify):	
see separate sheet						
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinior could be formed.				
		no international search report	t has b	een establish	ned for the said claims Nos.	
2.	A m or a Inst	A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative				
		l the written form has not been furnished or does not comply with the Standard.				
					ned or does not comply with the Standard.	
V.	Rea cita	asoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; ations and explanations supporting such statement				
1.	State	tement				
	Nov	elty (N)	Yes: No:	Claims Claims	1,4,7,13	
	Inve	ntive step (IS)	Yes: No:	Claims Claims	1,4,7,13	

1,4,7,13

Yes: Claims


Claims

No:

2. Citations and explanations

Industrial applicability (IA)

see separate sheet



#### ITEM III

Claim 14 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(I) PCT). See also the paragraph on : "Industrial applicability" in item V below.

#### ITEM V

Reference is made to the following documents:

D1: US 354772 D2: EP 547000 D3: WO0236563

#### NOVELTY (Article 33(2) PCT)


The preset subject matter overlaps with D1 and D2, of which is considered to be a novel selection on account of the present calcium salt of formula IA.

The present subject matter differs from D3 on on account of the present calcium salt of formula IA.

#### INVENTIVE STEP (Article 33(3) PCT)

D1 is considered to be the closest prior art and discloses indole derivatives, including present compound of formula IB, as inhibitors of HMG-CoA reductase. Although pharmaceutical acceptable cations are claimed (cf claim 1, definition of M), only Sodium and Potassium salts are specifically disclosed (cf examples, e.g. example 6, 8, 9, 22 and 39).

D2 discloses pharmaceutical composition comprising, inter alia, present compound of formula IB and carbonate salts, including sodium and calcium carbonate. The said carbonate are said in D2 to be inert to compound of formula I according to D2 (i.e. present compound of formula IB); it appears therefore that D2 ruled out the formation of present compound of formula IA during the formation of pharmaceutical composition according to claim 1 of D2 (cf. page 3, lines 20-28).



D3 discloses crystalline forms of the sodium salts derivative disclosed in D1.

The Applicants appears to have set themselves the target of providing salt derivative of compound of formula IB which have an increased stability at pH about 8 or below when compared to the salts derivative of the same compounds known from the prior art.

Present compounds of formula IA are proposed as a solution for the given problem. Neither D2 nor D3 provide information which might suggest that the calcium salt of compound of formula IA according to D1 have improved properties when compared to the corresponding sodium salt. However, also the present application does not provide any data which would clearly show, in a comparative matter, that the present salts have unexpected properties when compared with the closest prior art compounds, i.e. unexpectedly solve a problem not yet solved.

Accordingly an inventive step cannot be acknowledged for the present subject matter.

#### INDUSTRIAL APPLICABILITY (Article 33(4) PCT)

For the assessment of the present claim 14 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.